Anthem Biosciences Company Description
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization.
It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients.
The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry.
It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs.
The company was incorporated in 2006 and is based in Bengaluru, India.
| Country | India |
| Founded | 2006 |
| Industry | Commercial Physical and Biological Research |
| Employees | 1,825 |
| CEO | Ajay Bhardwaj |
Contact Details
Address: No. 49, F1 & F2, Canara Bank Road Bengaluru, Karnataka 560099 India | |
| Phone | 91 80 6672 4000 |
| Website | anthembio.com |
Stock Details
| Ticker Symbol | 544449 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Ajay Bhardwaj | Chief Executive Officer |
| Mohammed Baig | Chief Financial Officer |
| K. Chandrappa | Chief Operating Officer |